The role of rs1127354/rs7270101 alleles at the inosine triphosphatase (ITPA) gene on ribavirin-induced anemia was assessed in 74 patients with hepatitis C virus and human immunodeficiency virus coinfection. Anemia developed in 80% of patients with normal ITPA activity compared with 33% of those with reduced ITPA activity. In contrast, ITPA variants did not influence sustained virological response.
The addition of ribavirin to peginterferon-a (pegIFNa) significantly increases the rate of sustained virological response [1, 2] , especially in populations of patients that are difficult to treat, such as patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) [3, 4] . However, ribavirin-induced hemolytic anemia often forces dose adjustments, drug discontinuations, and/or use of erythropoietin, all of which complicate management and ultimately lead to reduced responses [5, 6] .
Well-established predictors of anemia in patients treated for chronic hepatitis C are older age, female sex, low platelet count, and low body weight [7, 8] . Two single-nucleotide polymorphisms (SNPs) at the inosine triphosphatase (ITPA) gene have recently shown to strongly influence the risk of ribavirininduced anemia [9] . A missense at exon 2 (rs1127354C.A) and a splice-alteration at intron 2 (rs7270101A.C) result in ITPA deficiency, which may protect from ribavirin-induced anemia. Although these results have been confirmed in HCV-monoinfected individuals [10, 11] , the impact of ITPA variants in HIV/ HCV-coinfected patients has not yet been examined.
METHODS
A pharmacogenetic substudy was conducted in HCV/HIVcoinfected patients enrolled in the Peginterferon Ribavirin Coinfection (PERICO) trial (ClinicalTrials.gov identifier: NCT00526448), an ongoing prospective, multicenter, openlabel study in which HCV/HIV-coinfected patients were randomized to receive pegIFNa-2a (180 lg/week) plus ribavirin at 2 different doses, standard dose (1000 or 1200 mg/day for body weight of ,75 kg or $75 kg, respectively) or high dose (2000 mg/day) plus erythropoietin (30 000 IU/week) during the first 4 weeks of therapy. After 4 weeks of treatment, all patients received standard ribavirin doses (1000 or 1200 mg/day). The trial aimed to demonstrate whether use of elevated ribavirin dosing supported from the beginning with erythropoietin might increase suppression of HCV replication [12] . To participate in this study, written informed consent for genetic testing including for ITPA polymorphisms was obtained from all individuals. The study protocol was evaluated and approved by the hospital ethics committee.
Anemia was assessed at week 4 of treatment and defined as absolute hemoglobin level decreases of $2 g/dL. The SNPs rs1127354 and rs7270101 at the ITPA gene were examined on DNA specimens collected from each individual using the 5# nuclease assay, as described elsewhere [9] .
ITPA genotypes carrying the minor allele (A for rs1127354, C for rs7270101), either in homozygosis or heterozygosis, were defined as protective genotypes because they have been associated with minimal ribavirin-induced anemia. The degree of ITPA deficiency was calculated by combining both ITPA variants according to their effect on ITPA activity, as described elsewhere [10] . Briefly, ITPA deficiency was 0% for rs11273554C/ C 1 rs7270101A/A, 40% for rs1127354C/C 1 rs7270101A/C, 70% for rs1127354C/A 1 rs7270101A/A, 70% for rs1127354C/ C 1 rs7270101C/C, 90% for rs1127354C/A 1 rs7270101A/C, and 90% for rs1127354A/A 1 rs7270101A/A.
All results are expressed in absolute values and percentages in the case of categorical variables and as median and interquartile range (IQR) for continuous variables. Proportions were compared using the Fisher exact test. Quantitative variables were compared using the Mann-Whitney U test. Univariate and multivariate linear regression analyses were performed to assess predictors of hemoglobin level decreases at week 4. All variables with P values of ,.2 in the univariate analysis were introduced into the multivariate analysis. All statistical analyses were performed using the SPSS package (version 13.0; SPSS, Chicago, IL), and significant differences were considered only for P values of , .05.
RESULTS
A total of 74 of 384 HIV/HCV-coinfected patients enrolled in the PERICO trial could be analyzed in this pharmacogenetic substudy. The rest could not be tested due to lack of either frozen material or informed consent for genetic testing. There were no significant differences between the tested population and the rest of the patients. Overall, 41 patients belonged to the ribavirin standard arm and 33 to the ribavirin induction group. The main baseline characteristics of this population are summarized in Table 1 . At baseline, the median hemoglobin level was 15.5 g/dL, the median serum HCV RNA level was 6.3 log IU/ mL, and 87% of patients harbored HCV genotypes 1 or 4. The mean CD4 cell count was 558 cells/lL, and 89% of patients had plasma HIV RNA levels of ,50 copies/mL, because the majority were receiving antiretroviral therapy. No patient was taking zidovudine or didanosine.
Both ITPA polymorphisms were in Hardy-Weinberg equilibrium (P . .05). The minor allele (A) frequency for rs1127354 was 0.05, and the minor allele (C) frequency for rs7270101 was 0.14. The distribution of the different ITPA genotypes for the 2 SNPs was as follows: for rs1127354, 90% CC, 10% CA, and 0% AA; and for rs7270101, 76% AA, 21% AC, and 3% CC; with no significant differences between treatment groups. The consideration of both polymorphisms led to prediction of distinct degrees of ITPA deficiency, as follows: no deficiency in 68% of patients, 40% deficiency in 20% of patients, 70% deficiency in 11% of patients, and .90% deficiency in the remaining 1% of patients. Overall, 32% of patients displayed some degree of ITPA deficiency. There were no significant differences between treatment groups.
Median hemoglobin level decreases at week 4 were 2.2 g/dL (IQR, 0.75-3.2 g/dL) and 2.5 g/dL (IQR, 1.7-3.1 g/dL) in ribavirin standard and ribavirin induction arms, respectively (P 5 .46). A total of 43 patients (63%) developed hemoglobin level decreases of $2 g/dL at week 4 of therapy, with the decreases being similar in both groups of patients. The proportion of patients with hemoglobin level decreases of $2 g/dL harboring the protective 
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Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; ITPA, inosine triphosphatase. a P , .05 for differences between both treatment arms.
versus the nonprotective rs1127354 and rs7270101 genotypes was 29% and 33% versus 67% and 74%, respectively (P 5 .045 and P 5 .002, respectively) ( Figure 1A ). Similar frequencies of these alleles were seen in the 2 treatment arms. When patients were stratified according to the degree of ITPA activity, anemia was significantly more frequent in those with normal ITPA activity than in those with any degree of deficiency (80% vs 33%, respectively; P , .001). The rate of anemia decreased in parallel with increased ITPA deficiency (80%, 40%, 25%, and 0% for patients with null, 40%, 70%, and .90% ITPA deficiency, respectively; P 5 .002) ( Figure 1B) . Similar rates of ITPA deficiency were seen in the 2 treatment arms.
In a linear regression analysis including age, sex, baseline hemoglobin levels, ribavirin dose, body weight, creatinine 
DISCUSSION
The development of ribavirin-induced hemolytic anemia is one of the most frequent adverse effects of current hepatitis C therapy, often forcing dose adjustments or even ribavirin discontinuation, which ultimately reduces the chances of cure. The use of erythropoietin may help to continue the use of ribavirin in some instances, but it is expensive and not available everywhere. In this substudy conducted in HIV/ HCV-coinfected patients enrolled in the PERICO trial [12] , we confirmed the protective role of minor alleles for SNPs rs1127354 and rs7270101 at the ITPA gene on the development of ribavirin-induced anemia. It must be highlighted that coinfected patients are particularly prone to developing anemia even when some concomitant antiretroviral medications, such as zidovudine, are not used [3] . To our knowledge, this is the first report assessing the impact of ITPA variants on anemia in HIV/HCV-coinfected patients treated with pegIFNa-ribavirin.
The frequency of the protective ITPA variants in our HCV/HIVcoinfected population was similar to that reported in previous studies conducted in HCV-monoinfected patients in other regions [9] [10] [11] . The rates of hemoglobin level decrease of $2 g/dL were significantly lower among patients harboring minor alleles for the ITPA variants; this was independent of the ribavirin dose treatment arm. Nearly one-third of our patients were predicted to have some degree of ITPA deficiency on the basis of ITPA haplotypes, and accordingly they were relatively protected from ribavirin-induced anemia. Altogether, our results support that ITPA genotyping might help therapeutic decisions in the HCV/ HIV-coinfection setting.
Given that high ribavirin exposure seems to enhance sustained virological rates [2] and that this effect might be more relevant in HIV/HCV-coinfected patients [3, 4] , individuals with ITPA deficiency might hypothetically benefit from using greater ribavirin doses, as the limitation of this strategy is development of anemia. In contrast, in patients with normal ITPA activity, standard ribavirin doses along with close monitoring of hemoglobin levels during the first weeks of therapy are warranted.
Given the study design of the PERICO trial, which provided erythropoietin along with high-dose ribavirin in 1 treatment arm, we could not assess properly to what extent ITPA variants might protect from elevated levels of ribavirin exposure. Our findings should encourage further studies to test whether the risk of anemia may be reduced and treatment responses increased with the use of higher ribavirin doses in patients with protective ITPA variants. The lack of recognition of an association between ITPA variants and sustained virological response rates in HCVmonoinfected individuals [9] [10] [11] and in our coinfected population does not preclude that an ITPA-guided ribavirin dosing might enhance treatment responses.
In summary, the minor alleles for the 2 functional variants at the ITPA gene, associated with ITPA deficiency, protects against development of ribavirin-induced anemia in HCV/HIV-coinfected patients treated for chronic hepatitis C. Thus, ITPA genotyping may help guide therapeutic decisions in this difficult-to-treat population.
